Published in FEBS Lett on October 19, 1987
Adenosine A1 and A2 receptors: structure--function relationships. Med Res Rev (1992) 1.62
Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des Discov (1992) 1.25
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists. J Med Chem (1992) 0.97
SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL 2-THIO DERIVATIVES OF ATP. Nucleosides Nucleotides (1993) 0.90
A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists. Nucleosides Nucleotides (1998) 0.85
Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. Proc Natl Acad Sci U S A (1996) 2.08
Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. Biochem Pharmacol (2000) 1.67
The concept of selectivity in 5-HT receptor research. Eur J Pharmacol (1990) 1.32
Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol (1996) 1.27
Role of ceramide 1 in the molecular organization of the stratum corneum lipids. J Lipid Res (1998) 1.20
Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol Pharmacol (2001) 1.18
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol (2000) 1.11
Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. 3. Regional distribution of pimozide and of haloperidol in the dog brain. Arzneimittelforschung (1968) 1.11
Pharmacological analysis of ecto-ATPase inhibition: evidence for combined enzyme inhibition and receptor antagonism in P2X-purinoceptor ligands. Br J Pharmacol (1994) 1.10
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Inhibition of receptor/G protein coupling by suramin analogues. Mol Pharmacol (1996) 1.04
Characterization of ecto-ATPase on human blood cells. A physiological role in platelet aggregation? Biochem Pharmacol (1993) 1.01
Conjunctival keratinisation, an abnormal reaction to an ocular beta-blocker. Acta Ophthalmol (Copenh) (1989) 0.98
A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. J Med Chem (1998) 0.97
Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res (2000) 0.97
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther (1997) 0.96
1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem (1991) 0.96
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. J Pharmacol Exp Ther (1999) 0.96
Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor. Mol Pharmacol (1999) 0.94
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor. J Med Chem (1992) 0.93
Suramin analogs, divalent cations and ATP gamma S as inhibitors of ecto-ATPase. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.93
Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. Mol Pharmacol (2000) 0.92
A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties. J Med Chem (1990) 0.91
Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacology (2007) 0.90
Dexetimide, a useful tool in acetylcholine-receptor localization. Eur J Pharmacol (1973) 0.89
Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats. Br J Pharmacol (1995) 0.88
Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor. Mol Pharmacol (1997) 0.87
The role of the second and third extracellular loops of the adenosine A1 receptor in activation and allosteric modulation. Biochem Pharmacol (2012) 0.87
The 5-HT1A receptor and its ligands: structure and function. Prog Drug Res (1999) 0.87
High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. J Chromatogr (1993) 0.86
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. J Med Chem (1995) 0.86
Identification of class-determining residues in G protein-coupled receptors by sequence analysis. Receptors Channels (1997) 0.85
Extracellular adenosine-induced apoptosis in mouse neuroblastoma cells: studies on involvement of adenosine receptors and adenosine uptake. Biochem Pharmacol (2001) 0.85
Mapping the N6-region of the adenosine A1 receptor with computer graphics. Eur J Pharmacol (1989) 0.85
5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol (2000) 0.85
Relative binding orientations of adenosine A1 receptor ligands--a test case for Distributed Multipole Analysis in medicinal chemistry. J Comput Aided Mol Des (1995) 0.84
The absolute configuration and crystal structure of the anticholinergic drug dexbenzetimide. Nature (1971) 0.84
Chemical modification of adenosine A1 receptors. Implications for the interaction with R-PIA, DPCPX and amiloride. Biochem Pharmacol (1990) 0.84
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. J Pharmacol Exp Ther (1997) 0.83
Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins. J Recept Res (1991) 0.83
Binding of the radioligand [35S]adenosine 5'-O-(2-thiodiphosphate) and intracellular calcium response in rat liver parenchymal cells. Biochem Pharmacol (1993) 0.82
Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. J Pharmacol Exp Ther (1995) 0.82
Interaction of amiloride and its analogues with adenosine A1 receptors in calf brain. Biochem Pharmacol (1990) 0.82
Novel competitive antagonists for P2 purinoceptors. Eur J Pharmacol (1994) 0.81
Relationships between structure and alpha-adrenergic receptor affinity of clonidine and some related cyclic amidines. Eur J Pharmacol (1981) 0.81
Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo. Br J Pharmacol (1995) 0.81
Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur J Pharmacol (1967) 0.80
Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats. J Pharmacol Exp Ther (1995) 0.80
The antiarrhythmic properties of beta-adrenoceptor antagonists. Trends Pharmacol Sci (1989) 0.79
Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists. J Pharmacokinet Biopharm (1997) 0.79
Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo. Br J Pharmacol (1996) 0.79
Mapping the xanthine C8-region of the adenosine A1 receptor with computer graphics. Eur J Pharmacol (1991) 0.79
The mode of interaction of amiloride and some of its analogues with the adenosine A1 receptor. Neurochem Int (1992) 0.78
Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue. Br J Pharmacol (2013) 0.78
2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes. Bioorg Med Chem Lett (2000) 0.78
Isolation of opioid-active compounds from Tabernaemontana pachysiphon leaves. J Pharm Pharmacol (1999) 0.78
Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016. Eur J Pharmacol (1994) 0.78
The metabolism and excretion of cinnarizine by rats. Life Sci (1968) 0.78
Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. J Pharmacol Exp Ther (1998) 0.77
Purification and characterization of enkephalin-degradating enzymes from calf-brain striatum. Biochem Biophys Res Commun (1983) 0.77
Localization of ( 3 H)pimozide in the rat brain in relation to its anti-amphetamine potency. J Pharm Pharmacol (1972) 0.77
Structure-affinity relationship studies on 5-HT1A receptor ligands. 2. Heterobicyclic phenylpiperazines with N4-aralkyl substituents. J Med Chem (1994) 0.77
Melanosome binding and oxidation-reduction properties of synthetic L-dopa-melanin as in vitro tests for drug toxicity. Mol Pharmacol (1988) 0.77
Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions. Pharm Weekbl Sci (1985) 0.76
Effects of halopemide on GABA receptor binding, uptake and release. Brain Res (1981) 0.76
Inhibition of nucleoside uptake in human erythrocytes by a new series of compounds related to lidoflazine and mioflazine. Eur J Pharmacol (1990) 0.76
A model of the serotonin 5-HT1A receptor: agonist and antagonist binding sites. Drug Des Discov (1994) 0.76
Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem (1992) 0.76
Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). Bioorg Med Chem Lett (2010) 0.75
Regional localization of halopemide, a new psychotropic agent, in the rat brain. Eur J Pharmacol (1978) 0.75
Opiate receptor interaction of compounds derived from or structurally related to fentanyl. J Med Chem (1981) 0.75
Research in the Division of Medicinal Chemistry. Pharm Weekbl Sci (1985) 0.75
The beta-adrenoceptor-adenylate cyclase complex. From model to biochemical reality. Pharm Weekbl Sci (1986) 0.75
The combined use of high-performance liquid chromatography and radioimmunoassay for the bioanalysis of nicomorphine and its metabolites. J Pharm Biomed Anal (1984) 0.75
[3H]batrachotoxinin-A 20-alpha-benzoate binding to sodium channels in rat brain: sensitivity to tetrodotoxin and divalent cations. Eur J Pharmacol (1988) 0.75
Effect of various enkephalin analogs and dipeptides on the enzymatic activity of enkephalinase B isolated from calf-brain striatum. Life Sci (1986) 0.75
Functional characteristics of a series of N4-substituted 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazines as 5-HT1A receptor ligands. Structure-activity relationships. Bioorg Med Chem Lett (1998) 0.75
Halopemide and benzodiazepine binding sites. Arch Int Pharmacodyn Ther (1982) 0.75
Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes. Eur J Pharmacol (1987) 0.75
Angiotensin converting enzyme inhibitors. Pharm Weekbl Sci (1982) 0.75
Computer modelling of the binding of non-selective ligands to biological receptors. Pharm Weekbl Sci (1983) 0.75
A series of N4-imidoethyl derivatives of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine as 5-HT1A receptor ligands: synthesis and structure-affinity relationships. J Med Chem (1995) 0.75
Inhibitors of calf-brain enkephalinase A and B. Life Sci (1983) 0.75
Improved qualitative method for establishing flunitrazepam abuse using urine samples and column liquid chromatography with fluorimetric detection. J Chromatogr (1986) 0.75
Influence of the molecular structure of N6-(omega-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity. Eur J Pharmacol (1989) 0.75
Molecular modelling of CCK-A receptors. Drug Des Discov (1994) 0.75
Adenosine-A1 receptors are not coupled to Ca2+ uptake in rat brain synaptosomes. Biochem Pharmacol (1989) 0.75
Structure-affinity relationship studies on 5-HT1A receptor ligands. 1. Heterobicyclic phenylpiperazines with N4-alkyl substituents. J Med Chem (1993) 0.75
Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. J Pharmacol Exp Ther (1996) 0.75
Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists. Eur J Pharmacol (1992) 0.75